Corticosteroids are commonly used in the peri-operative setting for patients undergoing cardiac surgery with cardiopulmonary bypass (CPB). The infl ammatory response to CPB is associated with organ dysfunction and increased mortality. Corticosteroids reduce biochemical infl ammatory markers associated with CPB, however the impact on clinical outcomes is mixed. The purpose of this article is to evaluate the evidence of changes in clinical outcomes associated with the peri-operative administration of corticosteroids in patients undergoing cardiac surgery with CPB. Randomized, placebo-controlled trials and meta-analyses were reviewed for evidence evaluating the impact of corticosteroids on clinical outcomes including mortality, myocardial infarction, atrial fi brillation (AF), duration of intubation, length of intensive care unit (ICU) or hospital stay, hyperglycemia, and gastrointestinal complications. Most of the relevant studies are underpowered to assess major clinical outcomes. Although corticosteroids likely reduce the risk of AF, this needs to be evaluated when used in addition to or in lieu of other anti-arrhythmic agents. Evidence does not equivocally support the use of corticosteroids to improve clinical outcomes in cardiac surgery patients.
A lthough commonly used in the peri-operative setting of cardiopulmonary bypass (CPB), corticosteroids have limited evidence of improving clinical patient outcomes. The anti-infl ammatory effects of corticosteroids are well studied, but they do not necessarily correlate with improved clinical outcomes. In 2004, guidelines from the American Heart Association recommended "liberal prophylactic use" based on the reduction in systemic infl ammation, however corticosteroids are no longer recommended in the 2011 guidelines. 1, 2 During CPB, blood is exposed to foreign materials causing the systemic release of infl ammatory markers including tumor necrosis factor-α and interleukin-6. 3 These substances have known cardio-depressant effects, although most patients recover normally postoperatively. For some, however, the infl ammatory response can cause hypotension and organ dysfunction. Infl ammation also causes impaired gas exchange and interstitial damage throughout the lungs. 4 Thus CPB-induced infl ammation could lead to worse outcomes including myocardial ischemia, cardiac arrhythmias, and prolonged respiratory failure.
The physiologic effects of corticosteroids can predict the potential benefi ts and risks. Through multiple mechanisms, corticosteroids minimize the CPB-induced infl ammatory response. They decrease capillary wall permeability, preventing migration of infl ammatory mediators into the systemic circulation. Corticosteroids also prevent the release of intracellular cytokines and subsequent adhesion to cell surfaces. Conversely, hyperglycemia, a well-known side effect, could contribute to impaired immune function and delays in wound healing. Renal effects can cause electrolyte and fl uid imbalances, leading to hemodynamic changes and cardiac instability. Gastrointestinal effects of corticosteroids could cause nausea, vomiting, and ulcerative bleeding. While the anti-infl ammatory effects are desirable, evidence of improved clinical outcomes is needed before recommending corticosteroids in the peri-operative setting. This review will summarize evidence from randomized controlled studies and meta-analyses that evaluate the impact of peri-operative use of corticosteroids on clinical outcomes.
METHODS
In addition to the Cochrane Review, 5 we searched MEDLINE and EMBASE for randomized controlled trials comparing corticosteroids to placebo in adult patients undergoing cardiac surgery. To search for applicable studies, medical subject headings, including steroid, corticosteroid, glucocorticoid, dexamethasone, prednisolone, prednisone, methylprednisolone, or hydrocortisone, were cross-referenced with cardiac surgery, cardiopulmonary bypass, and heart surgery. Studies or meta-analyses evaluating clinical outcomes including mortality, myocardial infarction, atrial fi brillation (AF), duration of intubation, intensive care unit (ICU) or hospital stay, hyperglycemia, and gastrointestinal complications were considered in this review. For the purpose of this review and similar to other authors, 6 the total daily dose of corticosteroid was classifi ed as low (less than 1,000 mg/day), moderate (1,000-10,000 mg/day), or high dose (more than 10,000 mg/day) of hydrocortisone equivalents.
RESULTS AND DISCUSSION Mortality and Myocardial Infarction
There are no studies powered to assess mortality or myocardial infarction as primary outcomes. After considering 49 studies including more than 3,200 patients, the Cochrane Review found no benefi t of corticosteroids in improving mortality in patients undergoing cardiac surgery (odds ratio [OR], 1.06; 95% confi dence interval [CI], 0.58-1.95). 5 The lack of a mortality benefi t persists after evaluating subgroups of studies using low doses only, as well as a combination of moderate to high doses of corticosteroids. Similarly, meta-analyses do not suggest any reduction in the risk of myocardial infarction associated with corticosteroids. 5, 7 The recently published Dexamethasone for Cardiac Surgery (DECS) study was a large, multi-center, randomized controlled trial. 8 In this study, 4,494 patients undergoing cardiac surgical procedures using CPB were randomized to receive dexamethasone 1 mg/kg (moderate dose) or placebo. There was no statistically signifi cant difference in the composite primary outcome of death, myocardial infarction, stroke, renal failure, or respiratory failure within 30 days of randomization between the corticosteroid or placebo groups (7% vs 8.5%; relative risk [RR], 0.83; 95% CI, 0.67-1.01; P = .07). Unfortunately, after all exclusions, only 20% of eligible patients were randomized, thus limiting the application of the results.
Atrial Fibrillation
AF occurs in 30% to 50% of patients following cardiac surgery and is associated with an increased incidence of stroke and prolonged length of stay. Several trials found that corticosteroids reduce the incidence of new onset AF following cardiac surgery, illustrating a correlation between infl ammation and AF. Corticosteroids were evaluated as part of a regimen including beta blockers to prevent AF in 2 studies. 9,10 One randomized, double-blinded, multicenter study of 241 cardiac surgery patients evaluated a low dose of hydrocortisone (100 mg following surgery, then 100 mg every 8 hours for 3 days). 9 Although a power analysis was not described, the incidence of new onset AF during the fi rst 84 hours after cardiac surgery was 48% in the placebo group compared to 30% in the hydrocortisone group (hazard ratio, 0.54; 95% CI, 0.36-0.82; P = .01). These results were consistent with a smaller but similar study, also using low dosing of corticosteroids (1,000 mg hydrocortisone prior to CPB followed by dexamethasone 4 mg every 6 hours for 1 day postoperatively). 10 Two meta-analyses evaluated the dose-dependent effect of corticosteroids on postoperative AF. 6, 11 To avoid signifi cant heterogeneity, Marik and colleagues excluded studies using doses less than 200 mg/day and more than 10,000 mg/day of hydrocortisone equivalents. 11 For the 2 studies that evaluated corticosteroids at these low and high ends of the dosing range, neither found signifi cant benefi t of corticosteroids in preventing AF. 12, 13 Within the remaining doses, corticosteroids reduced the incidence of AF compared to placebo by nearly 70% (OR, 0.32; 95% CI, 0.21-0.50; P < .0001) with insignifi cant heterogeneity between studies. Another meta-analysis showed a more modest reduction in the incidence of AF (25% vs 35%; RR, 0.74; 95% CI, 0.63-0.86; P < .01), and no differences between low, medium, or high dose strata. 6 Most of the studies included in either metaanalysis did not describe the use of perioperative beta-blocker therapy.
Even though the optimal regimen is unclear, evidence suggests a benefi cial effect of corticosteroids in Volume 49, March 2014 preventing postoperative AF in patients undergoing cardiac surgery. Further study is needed to determine if corticosteroids will further reduce the risk of AF when used in combination with or in lieu of other agents commonly used. Additionally, the benefi cial risk reduction of AF needs to be weighed against the potential side effects of corticosteroids.
Respiratory Failure
Prolonged intubation following cardiac surgery is associated with an increased risk of infection and a prolonged ICU length of stay. Evidence concerning the effects of corticosteroids on postoperative duration of intubation is confl icting and varies based on the corticosteroid doses studied. One randomized controlled trial of 90 patients undergoing elective cardiac surgery demonstrated prolonged time to extubation in patients receiving a cumulative high dose of 60 mg/kg methylprednisolone compared to those receiving 30 mg/kg or placebo (7.5 ± 2.7 vs 5.9 ± 2.2 vs 5.7 ± 2.3 hours; P = .04) despite no changes in fl uid balance, patient weight, or pulmonary hemodynamic variables between the groups. 14 Similarly, a meta-analysis found that high doses of corticosteroids were associated with a prolonged intubation by 2.1 hours (95% CI, 1.76-2.52; P < .01, without signifi cant heterogeneity). 6 While high doses may contribute to respiratory failure, evidence about moderate doses is confl icting. Three different randomized, placebo-controlled studies of moderate doses (Liakopoulos et al used methylprednisolone 15 mg/kg/day once prior to CPB; Oliver et al used methylprednisolone 1 g before induction then dexamethasone 4 mg every 6 hours for 4 doses; Yasser et al used dexamethasone 1 mg/kg at induction then 0.5 mg/kg 8 hours later) demonstrated no difference in ventilation time. [15] [16] [17] On the contrary, another study of moderate dose (dexamethasone 0.6 mg/kg after induction) in 236 patients undergoing elective surgery showed that whereas duration of ventilation was not statistically different between groups (11.6 ± 11.9 hours dexamethasone vs 13.1 ± 13.8 hours placebo, P = .074), the corticosteroid group had a larger percentage of patients with a short (6 hours or less) intubation time (10% vs 26%, P = .02) compared to placebo. 18 Most recently, analysis of secondary outcomes in the DECS study described above demonstrated a reduction in respiratory failure, defi ned as the need for mechanical ventilation for at least 48 hours postoperatively, in the group receiving a moderate dose corticosteroid (dexamethasone 1 mg/kg) compared to placebo (3% vs 4.3%; RR, 0.69; 95% CI, 0.51-0.94; P = .02). 8 Although there was little difference in the median time to weaning mechanical ventilation, the average time was higher in the placebo group (11 vs 14.3 hours; P < .001) due to a higher number of patients requiring prolonged (>24 hours) intubation in the placebo group (3.4 vs 4.9%; P value not reported).
One factor associated with prolonged duration of intubation is shivering, 18 which can be prevented with dexamethasone. 19 Given that shivering patients are commonly treated with opioid analgesics, a reduction in ventilator time may be related to a reduced need for opioids. One study showed a higher incidence of short (6 hours or less) intubation time in patients without shivering compared to those with shivering (23.6% vs 6.3%; P = .009). 18 The potential use of dexamethasone in preventing shivering, reducing opioid use, and shortening the duration of intubation needs further study.
Results of the Cochrane meta-analysis show no overall difference in time of mechanical ventilation with signifi cant heterogeneity (weighted mean difference, -1.8 minutes; 95% CI, -11.5 to 7.8). 5 Taken together, these results suggest the potential for a dose-dependent effect of corticosteroids prolonging intubation at high doses. Considering the confl icting evidence and results from the meta-analyses, corticosteroids may exert a positive effect on duration of intubation, but adequately powered controlled studies would be needed to confi rm this.
Length of Stay
Length of ICU or hospital stay has not been a primary outcome in any clinical trial, however they have been addressed in 3 meta-analyses with similar reductions for both parameters. [5] [6] [7] The Cochrane meta-analysis found a signifi cant reduction in ICU stay by about 2 hours (95% CI, -2.8 to -1.8 hours) and hospital stay by about half a day (95% CI, -0.65 to -0.15). The results of the 3 meta-analyses are similar, and they all had signifi cant heterogeneity between studies as a result of studies spanning 3 decades, including different corticosteroids at varying dosage regimens in different risk categories of patients. Therefore, any improvement in length of stay needs to be interpreted cautiously.
Hyperglycemia and Infectious Complications
Hyperglycemia is a well-known side effect of corticosteroids. Although changes in blood glucose concentrations represent a biochemical outcome, hyperglycemia is associated with impaired T-cell function and an increase in patient morbidity and mortality following cardiac surgery. 20 As expected, several clinical trials of corticosteroids have shown an increase in the incidence of hyperglycemia as well as higher insulin requirements. 15, 17, 18, 21, 22 The Cochrane analysis did not fi nd an increased risk of infection in 15 studies including infectious complications as secondary outcomes. 5 Given that no study has been suffi ciently powered to assess this outcome, there remains a theoretical increased susceptibility to infection and poor wound healing associated with hyperglycemia that has not been elucidated in the existing studies.
Gastrointestinal Complications
Corticosteroids are well known to increase the risk of peptic ulcers and other gastrointestinal complications. Since 1990, only 3 small studies involving a total of 204 patients have included gastrointestinal bleeding as a secondary outcome. 10, 12, 23 In the Cochrane meta-analysis, these 3 studies showed a trend of increased gastrointestinal bleeding in the corticosteroid groups (OR, 2.85; 95% CI, 0.4-20.36), although signifi cant heterogeneity existed between the studies (I 2 = 35%). 5
Ongoing Research
One large study is ongoing that is powered to assess major clinical outcomes. The steroids in cardiac surgery trial (SIRS) will enroll 7,500 adult patients and compare methylprednisolone 250 mg during induction and also prior to CPB (500 mg total) versus placebo. The primary endpoint is mortality at 30 days with secondary outcomes of myocardial infarction or mortality at 30 days and mortality at 6 months.
CONCLUSION
Although biochemical evidence of the antiinfl ammatory effect of corticosteroids is promising, existing clinical trials have not demonstrated an improvement in mortality or a reduction in myocardial infarction. The benefi cial effect of preventing AF with corticosteroids needs to be evaluated in combination with or in lieu of established agents. Any potential effect on shortening the duration of respiratory failure is promising, but requires further study. The result from meta-analyses about shorter length of stay is encouraging, but signifi cant heterogeneity including different drugs, doses, and study design limit the application of this outcome. The risks of corticosteroids related to hyperglycemia or gastrointestinal effects also require further study. The use of corticosteroids in patients undergoing cardiac surgery with CPB has not been shown to improve clinical outcomes beyond the standard of care in adequately powered randomized controlled trials and is not recommended.
